ATLANTA--(BUSINESS WIRE)--Amniox Medical, Inc., a developer and marketer of restorative therapies processed from amniotic membrane and umbilical cord, announces the relocation of its corporate headquarters from Marietta, GA, to Atlanta, GA. The Company’s new facility is located in the Vinings section of Atlanta and is more than double the size of its previous headquarters. The larger facility will accommodate the rapid expansion of the Company as a result of the successful penetration of its proprietary technology in the orthopedic and wound care markets.
Amniox Medical is the only provider of a human tissue matrix composed of both amniotic membrane and umbilical cord. These fetal tissues have innate regenerative properties that can be preserved and transplanted to other environments. The Company’s amniotic membrane/umbilical cord matrix comprises key proteins, cytokines and growth factors that have been shown to modulate inflammation and promote regeneration of normal tissue. Amniox utilizes its proprietary CryoTek™ process, a cryopreservation technology, to preserve the biological and structural integrity of these tissues.
Founded in 2011, Amniox Medical is a subsidiary of TissueTech, Inc. TissueTech has successfully served the ophthalmic market with this technology for more than fifteen years and more than 130,000 ophthalmic patients have experienced the anti-inflammatory properties, decreased scar tissue formation and analgesic benefits offered by this technology.
“We are very pleased to move into our new facility,” said Aaron Smith, General Manager of Amniox Medical. “Since our inception, the adoption of this technology in the orthopedic and wound care sectors has been rapid and we quickly outgrew the capacity at our original site. The new facility will allow us to add the professional staff that we need to accommodate the continued growth of our business. The added capacity will ensure that even more patients will enjoy the clinical benefits that are only offered by our unique technology. ”
Amniox Medical serves clinicians and patients in chronic wound care as a covering and in surgical applications where fibrosis and adhesions are a concern. Combined, these two applications can be used to address the treatment needs of more than three million patients annually in the United States.
Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, AMNIOX Medical is dedicated to developing and marketing restorative therapies processed from amniotic membrane and umbilical cord matrix utilizing its proprietary CRYOTEK technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products.
TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, more than 130,000 human implants have been conducted using the Company’s patented CryoTek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. The Company has pioneered the clinical application of human amniotic membrane and its role in stem cell research. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.